Zurich Pharma is a Mexican pharmaceutical company formed exclusively for the manufacture of highly specialized drugs. Zurich Pharma ensures the supply, availability and affordability of their products.
Zurich has an excellent Pharma Oncology portfolio that compares with any transnational level laboratory because their products are manufactured to the highest standards of quality and utilize unique technology in Mexico such as manufacturing liposome.
Contact
Address: Thiers No 40 col. Anzures, Miguel Hidalgo, México D.F. 11590. Mexico
Tel. (55) 6388 0616
Website: http://www.zurichpharma.com.mx/
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Diego Ocampo, Vice President of Technology at Neolpharma and President of the Mexican Foundation for Health Innovation (INCIDE), represents a new generation of pharmaceutical leadership combining global perspective with regional…
Carlos Abelleyra leads Medix, a 70-year-old Mexican pharmaceutical company undergoing a major strategic transformation. Since 2024, he has diversified the firm beyond its historical obesity focus, establishing divisions in vitamins,…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Fernando Zarate, Vice President of Bausch Health’s Latin American operations, outlines the company’s strategic positioning across the region. With 35 years in the industry and nearly two decades at Bausch…
Guy Savoir, CEO at Carnot Laboratorios, brings strategic vision to Mexico’s pharmaceutical reindustrialisation. Leading a company that has achieved balanced growth across Mexican and Latin American markets, he articulates an…
Ricardo Amtmann, President of Sanfer Group, discusses the company’s evolution from a licensing-dependent operation into Latin America’s most vertically integrated pharmaceutical enterprise. With nearly 14,000 employees across the region, Sanfer…
Adriana Eguia Alaniz is President of Tijuana EDC, leading efforts to diversify and strengthen the region’s economy. Under her leadership, Tijuana has strengthened its role as a major medical device…
Miguel Marti highlights Mexico as the Cardinal Health’s top market in Latin America, representing 25 percent of regional operations. Key priorities include thrombosis prevention, enteral nutrition, and surgical gloves. With…
Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments…
Some of the top recent stories out of Latin America’s dynamic pharmaceutical and healthcare market. In Mexico, President Claudia Sheinbaum announced new investments from four leading Mexican pharmas totalling USD…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
See our Cookie Privacy Policy Here
